Accurate and rapid quantification of EGFR mutation and PD-L1 expression status is of paramount importance in identifying of NSCLC patients more suitable for EGFR-TKI or ICI therapies, further guiding clinical decision-making. Here, CD274 is linked to non-small cell lung carcinoma.